Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma
Clinical Surgical Oncology · 2023
DOI: 10.1016/j.cson.2023.100020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Surgical Oncology, 2023. Verfasst von James M. Halle-Smith und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC) patients remain limited, meaning that death within weeks of diagnosis unfortunately remains a common occurrence. Whilst metastases from other malignancy sites, such as colorectal and breast, are amenable to resection in selected patients, consensus remains largely against resection of mPDAC. Without surgical resection, chemotherapy remains the main treatment option and despite advances in regimens, a large proportion of mPDAC patients do not respond to these treatments. Understandably, investigation into whether different genetic subtypes of PDAC can explain the changes in response to chemotherapy have been carried out but as yet has not demonstrated any marked differences between those that do and do not respond to chemotherapy treatment. This review outlines the emerging role that both the gut and tumour microbiome play in modulating the progression of PDAC, ranging from chemosensitivity to immune infiltration of the tumour This puts the gut microbiome in a promising position as a potential future therapeutic route for mPDAC patients. Possible methods to modulate the gut and tumour microbiome include antibiotics, probiotics and faecal microbiota transplantation (FMT). The next steps should therefore be to focus upon how we can effectively and safely introduce these beneficial bacteria into the gut and tumour microbiome of mPDAC patients through clinical trials.
Zitieren
APA
Halle-Smith, J. M., Hall, L. A., Powell-Brett, S. F., Merali, N., Frampton, A., & Roberts, K. J. (2023). Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma. Clinical Surgical Oncology. https://doi.org/10.1016/j.cson.2023.100020
Vancouver
Halle-Smith JM, Hall LA, Powell-Brett SF, Merali N, Frampton A, Roberts KJ. Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma. Clinical Surgical Oncology. 2023. doi:10.1016/j.cson.2023.100020
BibTeX
@article{HalleSmith2023,
author = {Halle-Smith, James M. and Hall, Lewis A. and Powell-Brett, Sarah F. and Merali, Nabeel and Frampton, Adam and Roberts, Keith J.},
title = {Realising the therapeutic potential of the human microbiota in metastatic pancreatic ductal adenocarcinoma},
journal = {Clinical Surgical Oncology},
year = {2023},
doi = {10.1016/j.cson.2023.100020}
}
EUVIMED